Medicare Law Causes Roche To Hesitate On Oncology Price Increases

Roche and Genentech are holding off on price increases in their oncology portfolio to avoid causing more confusion about reimbursement rates, Roche said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet